4600-86-6

Usage

Uses

Used in Fragrance and Flavor Industry:
5-tert-Butyl-2,3-dihydroinden-1-one is used as a key ingredient in the production of fragrances and flavors due to its appealing scent. Its pleasant odor makes it a valuable component in creating various fragrances and flavorings for consumer products.
Used in Pharmaceutical Industry:
5-tert-Butyl-2,3-dihydroinden-1-one serves as a crucial intermediate in the synthesis of pharmaceuticals. Its unique structure allows it to be a building block for the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 5-tert-Butyl-2,3-dihydroinden-1-one is utilized as a versatile intermediate for the preparation of various organic compounds. Its reactivity and stability make it suitable for use in the synthesis of a wide range of chemical products, including specialty chemicals and intermediates for further reactions.
Used in Research and Development:
5-tert-Butyl-2,3-dihydroinden-1-one is also employed in research and development settings, where its unique properties and reactivity are explored for potential applications in new chemical processes and innovative product development.
Overall, 5-tert-Butyl-2,3-dihydroinden-1-one is a valuable chemical compound with diverse applications in various industries, including fragrance and flavor production, pharmaceutical synthesis, organic chemistry, and research and development. Its unique structure, pleasant odor, high purity, and stability make it an essential component in the creation of new products and the advancement of scientific knowledge.

InChI:InChI=1/C13H16O/c1-13(2,3)10-5-6-11-9(8-10)4-7-12(11)14/h5-6,8H,4,7H2,1-3H3

Upstream product

• 28547-33-3 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one 
• 253185-03-4 tert-butylbenzene 
• 625-36-5 2-chloropropionyl chloride 
• 53987-61-4 3-(3'-t-Butylphenyl)-propionsaeure 

Downstream Products

• 808756-71-0 N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea 
• 934593-36-9 (1R)-5-tert-butyl-indan-1-ylamine tosylate 
• 808756-83-4 (1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 935680-90-3 5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 1178884-68-8 6-(tert-butyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1198764-90-7 C₁₃H₁₇NO 
• 4600-87-7 5-tert.-Butyl-2-(4-dimethylamino-benzyliden)-indanon-⁽¹⁾ 

Relevant academic research and scientific papers

PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combin

SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Preparation, physical properties and n-type FET characteristics of substituted diindenopyrazinediones and bis(dicyanomethylene) derivatives

A series of halogen and alkyl substituted diindenopyrazinediones and bis(dicyanomethylene) derivatives have been synthesized as new n-type organic semiconductors based on nitrogen-containing heterocycles. Halogen groups were introduced to improve the electron injection. Their crystal structures and solid physical properties are discussed. Alkyl groups were introduced to increase the solubility in organic solvents. Furthermore, hexanoyl groups were introduced by oxidation of alkyl groups to increase the solubility and electron affinity. Dicyanomethylene groups were also introduced to further enhance the electron-accepting properties. Drop-cast as well as vapour deposited thin films showed n-type FET properties.

SEROTONIN RECEPTOR MODULATORS

The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases.

INHIBITORS OF BURTON'S TYROSINE KINASE

This application discloses 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-V: wherein, variables Q, R, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

NOVEL PYRIDINONES AND PYRIDAZINONES

This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one deriva-tives according to generic Formulae I-III : wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat in-flammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole-N′-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of (R)-7 (ABT-102). Both the analgesic activity and drug-like properties of (R)-7 support its advancement into clinical pain trials.

Development of a large scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102

A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd